Lantheus Holdings, Inc. $LNTH Stock Position Increased by Resolute Capital Asset Partners LLC

Key Points

• Resolute Capital Asset Partners LLC increased its stake in Lantheus Holdings by 13.1%, acquiring an additional 15,888 shares, bringing its total ownership to 136,900 shares valued at approximately $13.36 million.
• Lantheus reported a quarterly EPS of $1.57, missing the consensus estimate of $1.65, with a revenue decline of 4.1% year-over-year to $378.05 million.
• Significant insider sales took place, including Farallon Partners selling 3.36 million shares for about $188.94 million, representing a 49.18% decrease in their position.

Resolute Capital Asset Partners LLC boosted its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 13.1% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 136,900 shares of the medical equipment provider's stock after acquiring an additional 15,888 shares during the quarter. Lantheus accounts for about 7.5% of Resolute Capital Asset Partners LLC's investment portfolio, making the stock its 3rd largest holding. Resolute Capital Asset Partners LLC owned approximately 0.20% of Lantheus worth $13,361,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Janus Henderson Group PLC lifted its position in Lantheus by 72.7% in the fourth quarter. Janus Henderson Group PLC now owns 6,198,689 shares of the medical equipment provider's stock valued at $554,583,000 after purchasing an additional 2,610,118 shares during the last quarter. Farallon Capital Management LLC raised its holdings in Lantheus by 79.9% during the 4th quarter. Farallon Capital Management LLC now owns 5,316,227 shares of the medical equipment provider's stock valued at $475,590,000 after buying an additional 2,361,000 shares during the last quarter. TD Asset Management Inc boosted its position in Lantheus by 1,028.0% during the 1st quarter. TD Asset Management Inc now owns 682,614 shares of the medical equipment provider's stock valued at $66,623,000 after buying an additional 622,100 shares during the period. Nuveen LLC purchased a new stake in Lantheus during the 1st quarter valued at $55,941,000. Finally, T. Rowe Price Investment Management Inc. grew its holdings in Lantheus by 40.5% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,509,332 shares of the medical equipment provider's stock worth $135,025,000 after acquiring an additional 435,445 shares during the last quarter. 99.06% of the stock is currently owned by institutional investors.

Lantheus Stock Up 2.1%

Shares of NASDAQ:LNTH traded up $1.18 during midday trading on Wednesday, reaching $56.84. The company's stock had a trading volume of 692,442 shares, compared to its average volume of 1,206,786. The company has a quick ratio of 4.07, a current ratio of 4.29 and a debt-to-equity ratio of 0.49. The firm has a 50 day moving average of $70.60 and a 200-day moving average of $83.77. The firm has a market capitalization of $3.86 billion, a P/E ratio of 15.12 and a beta of 0.14. Lantheus Holdings, Inc. has a 12-month low of $47.25 and a 12-month high of $118.21.

Lantheus (NASDAQ:LNTH - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The medical equipment provider reported $1.57 EPS for the quarter, missing the consensus estimate of $1.65 by ($0.08). Lantheus had a return on equity of 34.06% and a net margin of 17.82%.The business had revenue of $378.05 million for the quarter, compared to the consensus estimate of $389.69 million. During the same period in the previous year, the firm earned $1.80 EPS. The company's revenue was down 4.1% on a year-over-year basis. On average, research analysts anticipate that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Mary Anne Heino sold 26,066 shares of the company's stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $76.83, for a total value of $2,002,650.78. Following the transaction, the director directly owned 318,650 shares of the company's stock, valued at approximately $24,481,879.50. This represents a 7.56% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Farallon Partners L. L. C/Ca sold 3,365,000 shares of Lantheus stock in a transaction on Wednesday, August 20th. The stock was sold at an average price of $56.15, for a total value of $188,944,750.00. Following the completion of the sale, the insider directly owned 3,477,227 shares of the company's stock, valued at approximately $195,246,296.05. The trade was a 49.18% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 6,838,066 shares of company stock worth $384,430,031 in the last 90 days. Insiders own 2.00% of the company's stock.

Analyst Ratings Changes

A number of brokerages have recently weighed in on LNTH. Wall Street Zen upgraded Lantheus from a "hold" rating to a "buy" rating in a research report on Thursday, May 8th. Mizuho decreased their price objective on shares of Lantheus from $120.00 to $70.00 and set an "outperform" rating for the company in a report on Thursday, August 7th. B. Riley dropped their target price on shares of Lantheus from $122.00 to $109.00 and set a "buy" rating for the company in a research report on Monday, June 23rd. Truist Financial set a $63.00 price target on shares of Lantheus and gave the company a "hold" rating in a research report on Monday, August 11th. Finally, William Blair reissued a "market perform" rating on shares of Lantheus in a research note on Wednesday, July 16th. Five research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $105.50.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.